The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
AcTFirst: A phase 3 trial of 225Ac-PSMA-617 plus ARPI versus standard of care in adults with PSMA-positive metastatic castration-resistant prostate cancer.
 
Alton Sartor
Stock and Other Ownership Interests - Abbott Laboratories; Abbvie; Abdera Thereapeutics; Actithera; Advancell; Advancell; ARTbio; Asta; Azurna; BioNTech SE; Cardinal Health; Clarity Pharmaceuticals; Convergent Therapeutics; Curadh; Curadh; Lilly; NVision; Ratiopharm; Telix Pharmaceuticals; United Health Group
Honoraria - Actinium Pharmaceuticals; Advancell; AstraZeneca; Clarity Pharmaceuticals; Convergent Therapeutics; Intellisphere; Lantheus Medical Imaging; Pfizer; Point Therapeutics; Ratiopharm; Sanofi; Telix Pharmaceuticals
Consulting or Advisory Role - Abdera Thereapeutics; Actinium Pharmaceuticals; Actithera; Advancell; Alpha9; Amgen; ARTbio; Astellas Pharma; AstraZeneca; Bayer; Clarity Pharmaceuticals; Convergent Therapeutics; Curdah; Curium Pharma; Full Life; Fusion Pharmaceuticals; Isotopen Technologien; Janssen; Johnson & Johnson/Janssen; Lantheus Medical Imaging; Merck; Modex; Norroy; NorthStar; Novartis; Nucleus Radiopharma; NVision; Pfizer; Point Biopharma; Precede Bio; Progenics; Ratiopharm; Sanofi; Swiss Rockets; Syneos Health; Telix Pharmaceuticals; Telix Pharmaceuticals; Wren Laboratories; X-Cancer Software
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); Janssen; Lantheus Medical Imaging (Inst); Novartis (Inst)
Expert Testimony - Sanofi
Travel, Accommodations, Expenses - Bayer; Lantheus Medical Imaging; Sanofi
 
Louise Emmett
Consulting or Advisory Role - Advancell; Astellas Pharma; Clarity Pharmaceuticals; Novartis
Speakers' Bureau - Astellas Pharma (Inst); Janssen Oncology; mundipharma; Novartis
Research Funding - Clarity Pharma (Inst); Novartis (Inst); PCF (Inst); Telix Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Advancell
 
Karim Fizazi
Honoraria - Astellas Pharma (Inst); Bayer (Inst); Janssen (Inst); Novartis (Inst)
Consulting or Advisory Role - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo Europe GmbH (Inst); Janssen Oncology (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bayer; Janssen; MSD; Novartis; Pfizer
 
Andrei Iagaru
Consulting or Advisory Role - Alpha9Tx; Clarity Pharmaceuticals; Isotopen Technologien; Lilly; Novartis; Radionetics; Telix Pharmaceuticals
Research Funding - Advanced Accelerator Applications (Inst); GE Healthcare (Inst); Progenics (Inst)
Travel, Accommodations, Expenses - GE Healthcare
 
Ana Kiess
Research Funding - Bayer (Inst); Lantheus Medical Imaging (Inst); Novartis Pharmaceuticals UK Ltd.
Travel, Accommodations, Expenses - Physicans' Education Resource
(OPTIONAL) Uncompensated Relationships - AstraZeneca; Bayer; Novartis
 
Nobuaki Matsubara
Honoraria - Sanofi
Consulting or Advisory Role - Amgen; AstraZeneca; Janssen; Lilly; Pfizer; Sanofi; Seagen
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bayer Yakuhin (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Eisai (Inst); Janssen (Inst); Lilly (Inst); MSD (Inst); Novartis (Inst); Roche/Genentech (Inst); Seagen (Inst); Takeda (Inst)
 
Josep Piulats
Consulting or Advisory Role - Astellas Pharma; AstraZeneca/MedImmune; BeiGene; Bristol-Myers Squibb; Clovis Oncology; IDEAYA Biosciences; Immunocore; Janssen Oncology; Merck Sharp & Dohme; Pfizer; Roche/Genentech; VCN Biosciences
Research Funding - AstraZeneca/MedImmune; BeiGene; Bristol-Myers Squibb; Immunocore; Incyte; Janssen Oncology; Merck Sharp & Dohme; Mirati Therapeutics; Pfizer/EMD Serono
Travel, Accommodations, Expenses - AstraZeneca Spain; Bristol-Myers Squibb; Janssen Oncology; Pfizer; Roche
 
Fred Saad
Honoraria - Abbvie; Advanced Accelerator Applications; Astellas Pharma; AstraZeneca; Bayer; BMS; GlaxoSmithKline; Janssen Oncology; Knight Therapeutics; Merck; Myovant Sciences; Novartis; Pfizer; Sanofi; Sumitomo Dainippon Pharma Oncology; Tolmar
Consulting or Advisory Role - Abbvie; Advanced Accelerator Applications; Astellas Pharma; AstraZeneca/MedImmune; Bayer; GlaxoSmithKline; Janssen Oncology; Knight Therapeutics; Myovant Sciences; Novartis; Pfizer; Sanofi; Sumitomo Dainippon Pharma Oncology; Tolmar
Research Funding - Abbvie (Inst); Advanced Accelerator Applications (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Janssen Oncology (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Point Therapeutics (Inst); Sanofi (Inst)
 
Scott Tagawa
Stock and Other Ownership Interests - Convergent Therapeutics
Consulting or Advisory Role - 4D Pharma; Abbvie; Abdera Thereapeutics; AIkido Pharma; Ambrx; Amgen; Astellas Pharma; Bayer; Bicycle Therapeutics; Biohaven Pharmaceuticals; Blue Earth Diagnostics; Boston Scientific; Chugai Pharma; Clarity Pharmaceuticals; Clovis Oncology; Convergent Therapeutics; Daiichi Sankyo; Dendreon; Endocyte; Exelixis; Genentech; General Electric; Genomic Health; Gilead Sciences; Hookipa Pharma; Immunomedics; Janssen; Karyopharm Therapeutics; Lantheus Medical Imaging; Lilly; Medivation; Merck; Myovant Sciences; Novartis; Pfizer; POINT Biopharma; QED Therapeutics; Regeneron; Sanofi; Seagen; Telix Pharmaceuticals; Tolmar; TransThera Biosciences
Research Funding - Abbvie (Inst); AIQ Solutions (Inst); Ambrx (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AVEO (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Clarity Pharmaceuticals (Inst); Clovis Oncology (Inst); Dendreon (Inst); Endocyte (Inst); Exelixis (Inst); Genentech (Inst); Immunomedics (Inst); Inovio Pharmaceuticals (Inst); Janssen (Inst); Janux Therapeutics (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Medivation (Inst); Merck (Inst); Millennium (Inst); Newlink Genetics (Inst); Novartis (Inst); POINT Biopharma (Inst); Progenics (Inst); Rexahn Pharmaceuticals (Inst); Sanofi (Inst); Stem CentRx (Inst); Telix Pharmaceuticals (Inst)
Patents, Royalties, Other Intellectual Property - Patent Royalty from Immunomedics / Gilead
Travel, Accommodations, Expenses - Amgen; Astellas Pharma; Convergent Therapeutics; General Electric; Immunomedics; Lantheus Medical Imaging; Merck; Sanofi; Telix Pharmaceuticals
(OPTIONAL) Uncompensated Relationships - ATLAB Pharma; Phosplatin Therapeutics
 
Xiao Wei
Honoraria - OncLive
Consulting or Advisory Role - AstraZeneca; Dendreon; Novartis; Novartis; Novartis; Novartis; Novartis
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Macrogenics (Inst); Novartis (Inst); Poseida (Inst)
Travel, Accommodations, Expenses - Corvus Pharmaceuticals; Novartis
 
Jun Tang
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Shaheen Alanee
Employment - Novartis
Stock and Other Ownership Interests - Healthbio; Novartis; Tyra Biosciences
Consulting or Advisory Role - AstraZeneca; Merck Sharp & Dohme
Research Funding - BeyondSpring Pharmaceuticals; Merck; Merck Sharp & Dohme
 
Jeremie Calais
Honoraria - Advanced Accelerator Applications; Curium Pharma; EXINI Diagnostics; Novartis; Progenics; Radiomedix
Consulting or Advisory Role - Astellas Pharma; Blue Earth Diagnostics; Curium Pharma; GE Healthcare; Novartis; Nucleus Radiopharma; POINT Biopharma; Radiomedix; Telix Pharmaceuticals
Speakers' Bureau - Lantheus Medical Imaging; Novartis
Research Funding - Fusion Pharmaceuticals (Inst); Novartis (Inst); POINT Biopharma (Inst); Progenics (Inst); Telix Pharmaceuticals (Inst)